Evidence map›Paper›PMID 34674707›Full record

ArticleThrombosis journal2021

COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab.

Sufana Shikdar, Azra Borogovac, Elabdallah Mohamad, Mohamad Khawandanah

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thrombosis journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Sufana ShikdarDepartment of Hematology/Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 73104, Oklahoma City, United States, OK. Sufana.shikdar@gmail.com.
Azra BorogovacDepartment of Hematology/Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 73104, Oklahoma City, United States, OK.
Elabdallah MohamadDepartment of Internal Medicine, University of Oklahoma Medical Center (OUMC), 73104, Oklahoma City, United States, OK.
Mohamad KhawandanahDepartment of Hematology/Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 73104, Oklahoma City, United States, OK.
University of Oklahoma Health Sciences Center · USUniversity of Oklahoma Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the recent COVID19 pandemic, patients with hematological disorders were considered at high risk for severe disease. Limited data is available regarding the course of COVID19 infection in this subgroup. CASE PRESENTATION: We describe a case of a 32-year-old man with paroxysmal nocturnal hemoglobinuria (PNH) undergoing treatment with ravulizumab (Ultomiris) who presented with COVID19 infection. He experienced only mild symptoms and had a rapid recovery from COVID19 infection.

conclusionThis case may demonstrate the beneficial effects of ravulizumab on complement mediated inflammatory damage linked with COVID19 infection especially in PNH patients.

Indexed as

Complement inhibitorCOVID19Paroxysmal nocturnal hemoglobinuria

Identifiers

PMID34674707
PMCPMC8530370
OpenAlexW3119439294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.